David L. Bourdet, Ph.D.
Affiliations: | 2005 | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
Pharmacy, Pharmaceutical ChemistryGoogle:
"David Bourdet"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Dhiren R. Thakker | grad student | 2005 | UNC Chapel Hill | |
| (Novel mechanisms in the intestinal absorption of hydrophilic cationic drugs.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Belperio J, Nguyen T, Lombardi DA, et al. (2023) Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial. Bmj Open Respiratory Research. 10 |
| Pfeifer ND, Lo A, Bourdet DL, et al. (2021) Phase 1 study in healthy participants to evaluate safety, tolerability and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19. Clinical and Translational Science |
| Singh D, Bogus M, Moskalenko V, et al. (2021) A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. The European Respiratory Journal |
| Singh D, Bogus M, Moskalenko V, et al. (2021) A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. The European Respiratory Journal |
| Kanodia J, Lo A, Baldwin RM, et al. (2020) Pharmacokinetics of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, in Healthy Subjects and Adults with Attention-Deficit/Hyperactive Disorder or Fibromyalgia Pain. Clinical Pharmacokinetics |
| Kanodia J, Lo A, Baldwin RM, et al. (2020) Safety, Pharmacokinetics and Pharmacodynamics of TD-0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects. Clinical and Translational Science |
| Borin MT, Barnes CN, Darpo B, et al. (2019) Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study. Clinical Pharmacology in Drug Development |
| Donohue JF, Feldman G, Sethi S, et al. (2019) Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. Pulmonary Pharmacology & Therapeutics. 101808 |
| Czerniak R, Chen Y, Aldairy W, et al. (2019) Mo1581 – Evaluation of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of Tak–954 in a Randomized, Placebo-Controlled Phase 1 Study Gastroenterology. 156: S-789 |
| Kenna JG, Taskar KS, Battista C, et al. (2018) Can BSEP Inhibition Testing In Drug Discovery And Development Reduce Liver Injury Risk? - An International Transporter Consortium Perspective. Clinical Pharmacology and Therapeutics |